---
title: "Virtune lists the Virtune Hyperliquid ETP on Nasdaq Stockholm and Nasdaq Helsinki"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292048748.md"
description: "Today, a Swedish regulated crypto asset manager called Virtune announced the listing of the Virtune Hyperliquid ETP on Nasdaq Stockholm and Nasdaq Helsinki. Virtune, which was established in 2023, has gained the confidence of over 160,000 investors and currently oversees around USD 250 million in assets under management (AUM). This solidifies Virtune's status as a prominent issuer of regulated crypto ETPs in Europe. Additionally, the company dominates the market, holding over 90% market share for crypto ETNs on Nasdaq Nordics."
datetime: "2026-07-08T09:40:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292048748.md)
  - [en](https://longbridge.com/en/news/292048748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292048748.md)
---

# Virtune lists the Virtune Hyperliquid ETP on Nasdaq Stockholm and Nasdaq Helsinki

Today, a Swedish regulated crypto asset manager called Virtune announced the listing of the Virtune Hyperliquid ETP on Nasdaq Stockholm and Nasdaq Helsinki. Virtune, which was established in 2023, has gained the confidence of over 160,000 investors and currently oversees around USD 250 million in assets under management (AUM). This solidifies Virtune's status as a prominent issuer of regulated crypto ETPs in Europe. Additionally, the company dominates the market, holding over 90% market share for crypto ETNs on Nasdaq Nordics.

## Related News & Research

- [Qualcomm plans to increase prices by double digits](https://longbridge.com/en/news/293849857.md)
- [Alphabet, Amazon, and Meta Will Spend Over $500 Billion on AI in 2026. Nvidia Collects a Huge Share.](https://longbridge.com/en/news/293878735.md)
- [Shein swings to quarterly loss ahead of Hong Kong IPO](https://longbridge.com/en/news/293848513.md)
- [Shein reveals key financials ahead of Hong Kong IPO](https://longbridge.com/en/news/293847349.md)
- [Arovella Advances CAR-iNKT Programs as First Human Trial Nears](https://longbridge.com/en/news/293870724.md)